Nogapendekin Alfa Inbakicept

Summary

Nogapendekin Alfa Inbakicept (CHEMBL6068330) is an approved protein.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6068330
Name	Nogapendekin Alfa Inbakicept
Type	Protein
Max phase	4

Also known as: Anktiva, Nogapendekin alfa inbakicept, Nogapendekin alfa inbakicept-pmln, NOGAPENDEKIN ALFA INBAKICEPT

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE2	2
PHASE1	2
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07123727	PHASE2	RECRUITING	A Study to Examine Anktiva for the Treatment of COVID-19.
NCT07355205	PHASE2	NOT_YET_RECRUITING	First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
NCT07488884	PHASE1	NOT_YET_RECRUITING	Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer
NCT07217496	PHASE1	WITHDRAWN	N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
NCT07261657	EARLY_PHASE1	RECRUITING	N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).